| Junyuan, Qi |
NCT06558513: To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors |
|
|
| Recruiting | 1/2 | 176 | RoW | XNW5004 tablets | Evopoint Biosciences Inc., Shanghai Dingyue Biotechnology Co., LTD, Beijing Jiyingjia Medical Laboratory Co.,Ltd., Shanghai Jinghan Biological Technology Co., Ltd. | Advanced Tumor, Lymphoma | 12/24 | 12/24 | | |
| Yi, Shuhua |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 06/25 | 01/28 | | |
NCT04453345: TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL |
|
|
| Recruiting | 2/3 | 42 | RoW | thalidomide + prednisone + methotrexate, TPM regimen | Institute of Hematology & Blood Diseases Hospital, The First Affiliated Hospital of Nanchang University, First Affiliated Hospital of Guangxi Medical University, Henan Cancer Hospital, First Hospital of Jilin University, Central South University, Tianjin First Central Hospital | T-LGL Leukemia, Clpd-Nk | 05/23 | 05/25 | | |
NCT04463953: Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia |
|
|
| Recruiting | 2 | 55 | RoW | Zanubrutinib,Ixazomib and Dexamethasone | Institute of Hematology & Blood Diseases Hospital | Waldenström Macroglobulinemia | 05/23 | 05/25 | | |
NCT06415708: Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma |
|
|
| Recruiting | 2 | 134 | RoW | Obinutuzumab Combined With Bendamustine | Institute of Hematology & Blood Diseases Hospital, China | B Cell Lymphoma | 11/24 | 06/26 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
ZFCR/ZBR, NCT05287984: Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL |
|
|
| Not yet recruiting | 2 | 63 | RoW | Zanubrutinib, Fludarabine, cyclophosphamide and rituximab, ZFCR regimen, Zanubrutinib, bendamustine, rituximab, ZBR regimen | Institute of Hematology & Blood Diseases Hospital | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed | 06/24 | 11/24 | | |
ZGR, NCT06504199: Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 39 | RoW | Obinutuzumab, Zanubrutinib, Lenalidomide, Cytarabine, CAR-T | Institute of Hematology & Blood Diseases Hospital, China | Mantle Cell Lymphoma | 12/26 | 12/28 | | |
NCT06530576: Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia |
|
|
| Recruiting | 2 | 48 | RoW | Thalidomide and methotrexate | Institute of Hematology & Blood Diseases Hospital, China | T-LGL Leukemia, NK-LGL Leukemia | 07/26 | 07/27 | | |
NCT06530550: PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas |
|
|
| Recruiting | 2 | 51 | RoW | PI3K inhibitor | Institute of Hematology & Blood Diseases Hospital, China | Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia | 07/26 | 07/28 | | |
NCT06716658: JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/refractory Indolent T/NK-cell Lymphomas |
|
|
| Recruiting | 2 | 48 | RoW | JAK1 Inhibitor | Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Xijing hospital of air force Medical University, First Affiliated Hospital of Jilin University, The First Affiliated Hospital of Nanchang University, Henan Cancer Hospital, Second Xiangya Hospital of Central South University, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, China | Lymphoma, T-Cell, NK-LGL Leukemia, T-LGL Leukemia, Cutaneous T Cell Lymphoma, Cutaneous T Cell Lymphoma (CTCL), Large Granular Lymphocyte Leukemia, Large Granular Lymphocytic Leukemia, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Mycosis Fungoides | 11/26 | 11/28 | | |
| Recruiting | 2 | 42 | RoW | Zanubrutinib, Bendamustine and Rituximab | Institute of Hematology & Blood Diseases Hospital, China | Waldenstrom Macroglobulinemia | 03/25 | 12/25 | | |
NCT05846750: Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma |
|
|
| Recruiting | 2 | 59 | RoW | Obinutuzumab, GA101, lenalidomide | Institute of Hematology & Blood Diseases Hospital | Marginal Zone Lymphoma | 05/26 | 05/28 | | |
NCT04808570: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Terminated | 1/2 | 23 | RoW | TQ-B3525 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 11/23 | 11/23 | | |
NCT06464185: A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1/2 | 48 | RoW | Bispecific antibody-based combined with CAR-T cell therapy | Institute of Hematology & Blood Diseases Hospital, China | B-cell Non-Hodgkin Lymphoma | 04/26 | 04/27 | | |
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 1/2 | 123 | RoW | APG-2575, Rituximab, Ibrutinib | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 12/25 | | |
NCT05944978: A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies |
|
|
| Recruiting | 1/2 | 40 | RoW | GNC-035 | Sichuan Baili Pharmaceutical Co., Ltd. | Relapsed/Refractory Chronic Lymphocytic Leukemia | 08/25 | 08/25 | | |
| Recruiting | 1 | 191 | RoW | ICP-248, ICP-248+Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematological Malignancies | 08/25 | 10/26 | | |
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia |
|
|
| Completed | 1 | 46 | US, RoW | APG2575 400 mg, APG2575 600 mg, APG2575 800 mg | Ascentage Pharma Group Inc. | Waldenstrom Macroglobulinemia | 02/24 | 02/24 | | |
NCT05846763: Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study |
|
|
| Recruiting | N/A | 50 | RoW | | Institute of Hematology & Blood Diseases Hospital | Follicular Lymphoma | 05/26 | 05/28 | | |
